참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 1-Bromo-4-iodobenzene | HCID 11522 | — |
| 반응물 | rel-(2R,6S)-2,6-dimethylpiperazine | HCID 6950261 | — |
| 시약 | Sodium t-butoxide | HCID 23676156 | — |
| 촉매 | 1,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine) | HCID 636044 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | 1,4-Dioxane | HCID 31275 | — |
| 생성물 | 1-(4-Bromophenyl)-cis-3,5-dimethylpiperazine | HCID 66730361 | 44.14% |
반응 단계
sodium 2-methylpropan-2-olate (0.510 g, 5.30 mmol) was added to (2R,6S)-2,6-dimethylpiperazine (0.605 g, 5.30 mmol) in dioxane (40 mL) at 21°C under nitrogen. Stirred for 5 mins. 1-bromo-4-iodobenzene (1 g, 3.53 mmol) added, followed by diacetoxypalladium (0.079 g, 0.35 mmol) and (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (0.409 g, 0.71 mmol). Reaction evacuated and refilled with nitrogen several times. Heated at 90C for 18hours. left to cool o/w. The reaction mixture was diluted with EtOAc (250 mL), and washed sequentially with water (150 mL). The organic layer was dried over Na2SO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% MeOH in EtOAc. Pure fractions were evaporated to dryness to afford (3S,5R)-1-(4-bromophenyl)-3,5-dimethylpiperazine (0.420 g, 44.1 %) as a yellow solid.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-609b92e7f381461a936ff9653aaca797 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|